Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated?

Peritoneal Dialysis International

Volumn 21, Issue SUPPL. 3, 2001, Pages

  Hodsman, Anthony B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Diagnosis; Fractures; Osteoporosis; Pathophysiology; Renal transplant; Treatment

Indexed keywords

22 OXACALCITRIOL; ALENDRONIC ACID; ALFACALCIDOL; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM SALT; CLODRONIC ACID; COLECALCIFEROL; CYCLOSPORIN A; DOXERCALCIFEROL; ESTROGEN DERIVATIVE; ETIDRONIC ACID; IRON SALT; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARICALCITOL; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; VITAMIN D DERIVATIVE;

ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DIAGNOSTIC TEST; DIALYSIS; DRUG ABSORPTION; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT INDICATION; UREMIA;

EID: 0035570043     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102103s44     Document Type: Article

References (48)

1. Consensus development conference: Prophylaxis and treatment of osteoporosis
2. Morphologic basis of bone mineral measurements: Transient and steady state effects of treatment in osteoporosis
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
4. Corticosteroid-induced osteoporosis
5. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
6. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women
7. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism
8. Primary hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density following parathyroidectomy
9. Primary hyperparathyroidism and the risk of fracture: A population-based study
10. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
11. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
12. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
13. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
14. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postemopausal osteoporosis
15. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
16. Effect of risedronate on hip fracture risk in elderly women
17. Risk of new vertebral fractures in the year following a fracture
18. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
19. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and nonspine fractures and bone mineral density in postmenopausal osteoporosis
20. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis
21. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
22. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
23. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
24. Osteoporosis in end-stage renal disease
25. Fracture and bone mineral density in hemodialysis patients
26. Fractures and vertebral bone mineral density in patients with renal osteodystrophy
27. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures
28. Risk factors for hip fracture among patients with end-stage renal disease
29. The spectrum of bone disease in end-stage renal failure-an evolving disorder
30. Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function
31. Bone mineral density in patients with end-stage renal failure
32. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women
33. Bone densitometry: Patients with end-stage renal disease
34. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis
35. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
36. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function
37. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
38. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
39. 2) therapy for secondary hyperparathyroidism
40. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause
41. Hypercalcemic hyperparathyroidism following renal transplantation: Differential diagnosis, management, and implications for cell population control in the parathyroid gland
42. Rapid loss of vertebral mineral density after renal transplantation
43. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients
44. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation
45. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients
46. Increased fracture rate in diabetes mellitus and females after renal transplantation
47. Parathyroid hormone and bone metabolism in kidney-transplanted patients
48. Pamidronate therapy as prevention of bone loss following renal transplantation